Hookipa Pharma Inc. (HOOK) Stock Price & Analysis
Hookipa Pharma Inc. (HOOK) rose 0.00% to USD 1.15 as of June 10, 2026 at 03:34 UTC, according to Nexqual real-time market data.
HOOK last closed at USD 1.15; the session ranged USD 1.09–1.15 on volume of 315 shares. Market capitalization is $14.23M, with a 52-week range of USD 0.81–1.55 (PNK). Source: Nexqual, June 10, 2026 at 03:34 UTC.
Key Statistics (as of June 10, 2026 at 03:34 UTC)
| Price | USD 1.15 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.15 |
| Open | USD 1.09 |
| Day Range | USD 1.09 – 1.15 |
| 52-Week Range | USD 0.81 – 1.55 |
| Volume | 315 shares |
| Market Cap | $14.23M |
| Exchange | PNK |
Technical Analysis (HOOK)
Nexqual's technical model rates HOOK "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 03:34 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.84 (neutral) |
| vs SMA50 | Below (USD 1.15) |
| MACD | -0 (negative) |
Analyst Ratings (HOOK)
Wall Street analysts rate HOOK "None", per Nexqual as of June 10, 2026 at 03:34 UTC.
| Consensus Rating | None |
|---|
Earnings (HOOK)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-03-31 | USD -1.22 vs est -0.83 ▼ miss |
| 2024-12-31 | USD -0.74 vs est -0.69 ▼ miss |
| 2024-09-30 | USD -1.1 vs est -1.9 ▲ beat |
| 2024-06-30 | USD -1.52 vs est -1.25 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
Financials & Fundamentals (HOOK)
| Total Revenue | $9.35M |
|---|---|
| Revenue Growth (YoY) | -94.50% |
| Gross Margin | +0.00% |
| Operating Margin | -885.28% |
| Profit Margin | +0.00% |
| ROE | -105.79% |
| Debt / Equity | 1.75 |
| Current Ratio | 3.61 |
| Total Cash | $40.28M |
| Total Debt | $596,000 |
| Free Cash Flow | $-32.81M |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
Financial Health Score (HOOK)
Nexqual rates Hookipa Pharma Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:34 UTC.
| Growth | Strong — Revenue +118% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $40M cash, no debt |
| Cash Flow | Weak — FCF negative: -$33M, burning cash |
| Efficiency | Critical — ROE -106%, ROA -45.2% |
Ownership (HOOK)
| Insider Ownership | +0.13% |
|---|---|
| Institutional Ownership | +3.16% |
| Shares Outstanding | 9.98M |
| Float | 12.34M |
| Short % of Float | +0.45% |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
Leadership (HOOK)
Hookipa Pharma Inc. is led by Malte Peters (age 63), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:34 UTC.
| CEO, President & Director | Malte Peters (age 63) |
|---|---|
| Executive VP, CFO & Director | Mary Theresa Coelho (age 62) |
Major Backers & Investors (HOOK)
Notable institutional backers of Hookipa Pharma Inc. include Knoll Capital Management, LLC, Xtx Topco Ltd, according to Nexqual as of June 10, 2026 at 03:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Knoll Capital Management, LLC | 5% |
| Xtx Topco Ltd | 0.18% |
Source: Nexqual, June 10, 2026 at 03:34 UTC.
From Hookipa Pharma Inc.'s Latest SEC 10-K Filing (filed 2025-02-28)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed a pipeline of product candidates and intend to pursue clinical development of additional product candidates utilizing our non-replicating and replicating technologies.
Partnerships
- Risks Related to Our Reliance on Third Parties We are fully dependent on our collaboration with Gilead for the development of our HBV programs, rely on funding from Gilead for development of our human immunodeficiency virus program, and may depend on Gilead or additional third parties for the development and commercialization of our other programs and future product candidates.
- Any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our other product candidates, which would harm our business prospects, financial condition, and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GOSS | Gossamer Bio, Inc. | USD 0.16 | ▼ 8.57% |
| KLDO | Kaleido Biosciences, Inc. | USD 0 | ▲ 0% |
| DTIL | Precision BioSciences, Inc. | USD 6.86 | ▲ 5.54% |
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
| PASG | Passage Bio, Inc. | USD 5.57 | ▼ 0.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:34 UTC. This page is informational and not investment advice.